Responses to anti-angiogenic therapies

A. S. Paller*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Vascular tumors occur in approximately 10% of infants, and range from small cherry-red lesions to large, life-threatening tumors. Although the majority of these tumors involute after several years, there are few therapeutic options and their use is limited by the risk of side-effects. The recent increase in understanding of angiogenesis has led to investigations of new antiangiogenic treatment options using models of vascular tumors in mice. These studies have demonstrated the success of a variety of antiangiogenic approaches, including systemic administration of the antiangiogenic proteins AGM-1470 and angiostatin or of the matrix metalloproteinase inhibitor batimastat, and gene gun therapy with interleukin-12. Although these trials provide further evidence of the role of angiogenesis in the enlargement of these vascular tumors, their potential utility and safety await future trials in patients.

Original languageEnglish (US)
Pages (from-to)83-86
Number of pages4
JournalJournal of Investigative Dermatology Symposium Proceedings
Issue number1
StatePublished - 2000


  • Angiogenesis
  • Hemangiomas
  • Kasabach-Merrit syndrome

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Biology
  • Dermatology
  • Cell Biology

Fingerprint Dive into the research topics of 'Responses to anti-angiogenic therapies'. Together they form a unique fingerprint.

Cite this